Quelle biothérapie choisir en fonction des caractéristiques de l’asthme sévère chez l’adulte ?
Authors:
- 26 April 2023
- journal article
- review article
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 207 (5) , 612-618
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsThe Lancet Respiratory Medicine, 2015
- The prevalence of severe refractory asthmaJournal of Allergy and Clinical Immunology, 2015
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabJournal of Allergy and Clinical Immunology, 2014
- Omalizumab, an anti-immunoglobulin E antibody: state of the artDrug Design, Development and Therapy, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysisJournal of Allergy and Clinical Immunology, 2013
- Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohortArthritis Research & Therapy, 2012
- Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean “real-life” experiencePulmonary Pharmacology & Therapeutics, 2012